Inclusion Criteria:

●≥ 18 and ≤ 70 years of age.

- ECOG performance status of 0-1.

- Metastatic breast cancer, confirmed by histological analysis.

- Have experienced at least 1 and at most 4 regimens, and failed from the last
chemotherapy regimen. Pretreated anthracycline, taxanes and capecitabine (any
rational reason for no use of capecitabine is acceptable) are mandatory.

- Women diagnosed with human epidermal growth factor receptor positive (HER2+) should
have failed for at least 1 anti-HER2 therapy (any rational reason for no use of
anti-HER2 therapy is acceptable). HER2+ is defined as +++ staining on
immunohistochemistry or FISH/CISH positive for gene amplification.

- Women diagnosed with HR+ should have failed for at least 1 hormonal therapy.

- Have failed for at least one chemotherapy regimen, but at most three
regimens(including adjuvant and neo-adjuvant setting).

- Duration from the last therapy (chemotherapy, radiotherapy, target therapy and
operation) is more than 4 weeks (Duration for nitroso or mitomycin is 6 weeks).

- Have at least one extracranial measurable site of disease according to RECIST 1.0
criteria that has not been previously irradiated.

- Life expectancy of more than 3 months.

- Negative serum or urine pregnancy test taken in all women within 7 days before
inclusion. Sexually active women of childbearing potential must use a medically
acceptable form of contraception from the beginning of the study to 8 weeks after the
last dose of the investigated drug.

- Written informed consent prior to study specific screening procedures.

Exclusion Criteria:

- Triple-negative breast cancer (ER-, PR- and HER2-. HER2- is defined as 0 or 1+
staining on immunohistochemistry or FISH/CISH negative for gene amplification. )

- Pregnant or lactating women.

- Less than 4 weeks from the last clinical trial.

- Uncontrolled hypertension with mono-drug therapy (＞140/90 mm Hg)；ischemia of the
myocardium （≥ grade 2） or myocardial infarction；arrhythmia（≥ grade 2, QTcF ＞ 470ms
for female patients） or New York Heart Association Class III/IV

- Any factors that influence the usage of oral administration.

- The cumulative doses of doxorubicin and epirubicin before inclusion have surpassed
300 mg/m2 and 600 mg/m2, respectively.

- Duration from the last therapy (chemotherapy, radiotherapy, target therapy and
operation) is less than 4 weeks (Duration for nitroso or mitomycin is less than 6
weeks).

- Confirmed brain metastasis.

- Inadequate hepatic, renal, heart, and hematologic functions (hemoglobin ＜90g/L,
neutrophils ＜ 1.5×10^9/L, platelets ＜ 80×10^9/L , ALT ＞ 2.5 x upper limit of normal
(ULN)(5x for liver metastasis), AST ＞ 2.5 x ULN (5x for liver metastasis), serum
bilirubin ＞ 1.5 x ULN, serum creatine ＞ 1.0 x ULN, creatinine clearance rate ≤
50ml/min, LVEF ＜ lower limit of normal (LLN).

- Abnormal coagulative function, inclined to bleeding or is receiving
thrombolytictherapy or anticoagulation.

- History of arterial/venous embolic events (such as cerebrovascular accident, TIA,
deep vein thrombus,and pulmonary embolism)

- Unhealed wound (＞ 30 days) or bone fracture.

- Urine protein ≥++ and confirmed ＞1.0 g by the 24h quantity.

- Previous or present history of pulmonary fibrosis,interstitial
pneumonia,pneumoconiosis,radiation pneumonitis,drug-related pneumonitis or
greatly-impaired pulmonary function.

- Disability of serious uncontrolled intercurrence infection.

- Abuse of alcohol or drugs.

- Have received prior treatment with a VEGFR, PDGFR or s-SRC TKI (Bevacizumab is
permitted).

- Acquired or inherent immunodeficiency； HIV infection； organ transplantation history.

- The active HBV or HCV infection or HBV DNA ≥10^4/ml.

- History of other malignancies except cured basal cell carcinoma of skin and carcinoma
in-situ of uterine cervix.

- Presence of serious harm to subjects or complication to hinder the completion of the
study judged by investigators